PCR Markets 2027–2031

PCR Markets: Market Forecast, Competitive Landscape, Company Revenue Estimates, Technology and Policy Outlook, 2027–2031 (9th Edition)

Global forecasts for qPCR, digital PCR, sample-to-answer cartridge and end-point PCR by application, technology, plex, product and setting, for 14 countries and regions, with HSR’s estimates of each major supplier’s PCR revenue and 38 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

PCR is moving into the cartridge. This revised edition rebuilds the market from the bottom up, supplier by supplier, and finds a larger, more clinical market than earlier estimates: $15,455.0 million in 2026, growing 5.4% a year to $20,072.7 million in 2031. Clinical Infectious Disease is 65.5% of the market, and growth is held back as respiratory testing normalises after the pandemic years, while sample-to-answer cartridges, syndromic panels, digital PCR, oncology and biopharma QC take the growth.

Market Size 2026: USD $15.46B Market Size 2031: USD $20.07B CAGR: 5.4%

Situation Analysis: what is really happening

• PCR moves into the cartridge. Sample-to-Answer Cartridge PCR grows 7.0% a year and rises from 36.6% to 39.5% of the market, while qPCR falls from 50.6% to 47.4%.
• Panels replace single tests. Syndromic Panels (6+) grow 9.6% a year, from $2,795.4 million to $4,414.8 million; Cepheid won FDA clearance for its 13-target Xpert Respiratory Panel in September 2026.
• The respiratory reset. bioMérieux cut its 2026 guidance after BIOFIRE respiratory sales fell, and Danaher’s respiratory testing fell to about $350 million in the third quarter of 2026. Clinical Infectious Disease grows 4.5% a year.
• Digital PCR and biopharma QC lead growth. Digital PCR is the fastest-growing line at 11.0% a year, Biopharma QC & Cell/Gene Therapy grows 9.7% and Oncology & Genetic Testing 9.2%.
• New owners. EQT agreed to take QIAGEN private, Blackstone and TPG completed the take-private of Hologic, Waters completed its combination with BD’s diagnostics business, QuidelOrtho completed its acquisition of LEX Diagnostics and Roche acquired SAGA Diagnostics.
• Payment and trade pressure. CMS published preliminary 2027 lab fee rates, China’s pricing reforms cut test prices, and US tariff policy changed after the Supreme Court’s IEEPA ruling.

Company Analysis: who is positioned, who is exposed

• Roche, Cepheid (Danaher), bioMérieux, Abbott, Hologic and Waters (BD MAX, BD COR): Automated laboratory and sample-to-answer clinical PCR and syndromic panels, with HSR’s estimates of each company’s PCR revenue and ranges.
• Thermo Fisher Scientific, QIAGEN and Bio-Rad Laboratories: qPCR, digital PCR, extraction and clinical PCR across research, biopharma and the clinic.
• Seegene, Sansure Biotech, Da An Gene, Tianlong Technology, BGI Genomics, Beijing TargetingOne, SD Biosensor and Bioneer: Asian makers of multiplex, low-cost and digital PCR.
• QuidelOrtho, Visby Medical, Bosch, Molbio, Mylab, Credo, Diasorin and Biocartis: Fast, point-of-care and cartridge PCR systems.
• Promega, New England Biolabs, Integrated DNA Technologies, Takara Bio, Agilent, Eppendorf, Revvity, Meridian Bioscience and Biomark Scientific: Enzymes, reagents, oligos, extraction, cyclers and microfluidics.
• altona Diagnostics, R-Biopharm, Bruker (ELITechGroup and Hain Lifescience) and SpeeDx: Specialist clinical and applied PCR assays.

In all, 38 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Inside the report: HSR’s revenue estimate for every named company, with low–high ranges, and a growth and share-change map of every application and technology line. Names and values are in the full report.

Questions this report answers

• How large is the PCR market when it is built company by company, and where is growth fastest?
• How much PCR revenue do Roche, Cepheid, bioMérieux, Thermo Fisher, QIAGEN, Bio-Rad and other suppliers earn?
• How fast are cartridges and syndromic panels replacing single tests, and how deep is the respiratory reset?
• What do the QIAGEN, Hologic, BD and LEX changes of ownership mean for customers and competitors?
• How will lab fee cuts, tariffs, research funding and China’s pricing reforms affect suppliers?
• How large is each country market, and where is growth fastest?

What's inside

• 422 pages, 23 chapters, 149 tables and 58 figures
• Forecasts for 2027–2031 from a 2026 base year, by application, technology, plex, product and setting, for 14 countries and regions
• HSR’s estimates of supplier PCR revenue with low–high ranges, and a growth and share-change map of every application and technology line
• Clinical PCR; research, biopharma and applied PCR; and a dedicated digital PCR chapter
• Technology landscape, products and business models, regulation and reimbursement, operations, and China, Asia-Pacific and emerging markets; IVD – The Big Picture
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 38 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostic and life science companies: size markets, benchmark competitors and plan platforms and menus.
• Laboratories and health systems: plan instrument purchases and test menus as payment tightens.
• Investors and analysts: model a market reshaped by take-privates, mergers and the respiratory reset.
• Biopharma and applied testing users: understand the suppliers and technologies for QC, food, environmental and forensic PCR.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.